Citalopram p.o

PreclinicalSmall molecule

IIstituto Auxologico Italiano

Citalopram p.o is one of 40 small molecule programs targeting Anorexia Nervosa. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anorexia NervosaActive, not recruiting

Anorexia NervosaPreclinical

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Anorexia Nervosa

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

6 2

Abilify

Otsuka

Approved

2 3

Risperdal

WWim Janssens

Approved

1 4

Prometrium

Pitocin

Remeron

Prolia

1 8

Zometa

Pfizer

Phase 3

1 9

Marinol

Alnylam Pharmaceuticals

Phase 3

1 10

Aricept

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anorexia Nervosa1 trial

Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Anorexia Nervosa.

Unknown status·IIstituto Auxologico Italiano··NCT05795283·123 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Citalopram p.o. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Citalopram p.o compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Citalopram p.o. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Istituto Auxologico Italiano company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIstituto Auxologico Italiano

Citalopram p.o

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anorexia Nervosa1 trial

References

Drug Info

Quick Facts

Related News